<DOC>
	<DOCNO>NCT00741715</DOCNO>
	<brief_summary>The present study assess efficacy safety AVE5530 ( 25mg 50mg ) co-administered approved dos atorvastatin double-blind comparison placebo , AVE5530 alone atorvastatin alone management patient primary hypercholesterolemia . The main objective evaluate effect association AVE5530+atorvastatin LDL-C level reduction 12 week treatment . The effect AVE5530+atorvastatin lipid parameter assess secondary objective</brief_summary>
	<brief_title>Evaluation Efficacy Safety AVE5530 Co-administered With Atorvastatin Primary Hypercholesterolemia</brief_title>
	<detailed_description>The study include 2 week pre-randomization placebo lead-in phase . There 12- week double-blind treatment period component AVE5530 atorvastatin , follow 40-week period maintenance double-blind design AVE5530 component open label atorvastatin component transition 20 mg patient subsequent titration , necessary , base regular LDL-cholesterol monitoring . The treatment period variably extend approximately 18 month double-blind AVE5530 component open-label atorvastatin .</detailed_description>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<criteria>Adults high cholesterol level either receive willing able discontinue ongoing lipidlowering therapy LDLC level &gt; 250 mg/dL ( 6.48 mmol/L ) Triglycerides level &gt; 350mg/dL ( 3.95 mmol/L ) Conditions / situation : presence clinically significant uncontrolled endocrine disease know influence lipid level Active liver disease High estimate risk Coronary Heart Disease Recent history congestive heart failure , unstable angina pectoris , myocardial infarction , coronary bypass surgery angioplasty , Unstable severe peripheral artery disease Positive test Hepatitis B surface antigen and/or Hepatitis C antibody Known Human Immunodeficient Virus ( HIV ) positive Pregnant breastfeeding woman , Women childbearing potential protected effective contraceptive method birth control ( include oral contraceptive ) and/or unwilling unable test pregnancy prior exposure Investigational Product Hypersensitivity component atorvastatin Concurrent administration Cytochrome P450 3A4 inhibitor ( e.g . cyclosporine , erythromycin , clarithromycin , azole antifungal ) avoid increase risk myopathy atorvastatin The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>primary hypercholesterolemia</keyword>
</DOC>